A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers. Issue 1 (31st December 2022)
- Record Type:
- Journal Article
- Title:
- A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers. Issue 1 (31st December 2022)
- Main Title:
- A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers
- Authors:
- Heads, James T.
Kelm, Sebastian
Tyson, Kerry
Lawson, Alastair D. G. - Abstract:
- ABSTRACT: The propensity for some monoclonal antibodies (mAbs) to aggregate at physiological and manufacturing pH values can prevent their use as therapeutic molecules or delay time to market. Consequently, developability assessments are essential to select optimum candidates, or inform on mitigation strategies to avoid potential late-stage failures. These studies are typically performed in a range of buffer solutions because factors such as pH can dramatically alter the aggregation propensity of the test mAbs (up to 100-fold in extreme cases). A computational method capable of robustly predicting the aggregation propensity at the pH values of common storage buffers would have substantial value. Here, we describe a mAb aggregation prediction tool (MAPT) that builds on our previously published isotype-dependent, charge-based model of aggregation. We show that the addition of a homology model-derived hydrophobicity descriptor to our electrostatic aggregation model enabled the generation of a robust mAb developability indicator. To contextualize our aggregation scoring system, we analyzed 97 clinical-stage therapeutic mAbs. To further validate our approach, we focused on six mAbs (infliximab, tocilizumab, rituximab, CNTO607, MEDI1912 and MEDI1912_STT) which have been reported to cover a large range of aggregation propensities. The different aggregation propensities of the case study molecules at neutral and slightly acidic pH were correctly predicted, verifying the utility ofABSTRACT: The propensity for some monoclonal antibodies (mAbs) to aggregate at physiological and manufacturing pH values can prevent their use as therapeutic molecules or delay time to market. Consequently, developability assessments are essential to select optimum candidates, or inform on mitigation strategies to avoid potential late-stage failures. These studies are typically performed in a range of buffer solutions because factors such as pH can dramatically alter the aggregation propensity of the test mAbs (up to 100-fold in extreme cases). A computational method capable of robustly predicting the aggregation propensity at the pH values of common storage buffers would have substantial value. Here, we describe a mAb aggregation prediction tool (MAPT) that builds on our previously published isotype-dependent, charge-based model of aggregation. We show that the addition of a homology model-derived hydrophobicity descriptor to our electrostatic aggregation model enabled the generation of a robust mAb developability indicator. To contextualize our aggregation scoring system, we analyzed 97 clinical-stage therapeutic mAbs. To further validate our approach, we focused on six mAbs (infliximab, tocilizumab, rituximab, CNTO607, MEDI1912 and MEDI1912_STT) which have been reported to cover a large range of aggregation propensities. The different aggregation propensities of the case study molecules at neutral and slightly acidic pH were correctly predicted, verifying the utility of our computational method. … (more)
- Is Part Of:
- MAbs. Volume 14:Issue 1(2022)
- Journal:
- MAbs
- Issue:
- Volume 14:Issue 1(2022)
- Issue Display:
- Volume 14, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 14
- Issue:
- 1
- Issue Sort Value:
- 2022-0014-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-12-31
- Subjects:
- Developability -- aggregation -- prediction -- hydrophobicity -- charge -- antibody -- homology modeling -- isotype -- IgG1 -- IgG4
Monoclonal antibodies -- Therapeutic use -- Periodicals
Monoclonal antibodies -- Periodicals
Antibodies, Monoclonal -- Periodicals
616.0798 - Journal URLs:
- http://www.tandfonline.com/loi/kmab20#.VufTUVLcuic ↗
http://www.landesbioscience.com/journals/mabs ↗
http://www.tandfonline.com/ ↗ - DOI:
- 10.1080/19420862.2022.2138092 ↗
- Languages:
- English
- ISSNs:
- 1942-0862
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5320.243000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24613.xml